Skip to main content

Market Overview

Pfizer Should Outperform, Morgan Stanley Upgrades

Pfizer Should Outperform, Morgan Stanley Upgrades

Analysts at Morgan Stanley turned bullish on Pfizer Inc. (NYSE: PFE) amid multiple catalysts and accretive M&A opportunities ahead.

Analyst David Risinger upgraded Pfizer's stock from Equal-weight to Overweight with a price target boosted from $35 to $39.


Pfizer's pipeline is encouraging, especially in the breast cancer space where the company's Ibrance therapy could prove to be one of the "world's top drugs" as soon as next decade, Rissinger said. Ibrance could see sales in the $5 to $6 billion range by the end of the decade and then rapidly accelerate to $11 billion in 2023.

The drugmaker also has two Phase 3 adjuvant trials that are expected to be complete by 2020, including PALLAS which compares Ibrance and a standard endocrine therapy. In fact, to the best of the analyst's knowledge, none of Pfizer's competitors have even started any large adjuvant trials while Pfizer is evaluating its drug among 4,600 patients with stage two or three breast cancer.

The other phase 3 trial, PNELOPE-B, compares Ibrance versus a placebo among 1,250 patients who have residual disease after e after neoadjuvant chemotherapy and therefore have a high risk of recurrence.

Deferred Tax Liability

Pfizer's balance sheet adds another layer to the company's bullish outlook, Risinger added. The company's $23.1 billion in deferred tax liability associated with unremitted earnings implies it can benefit "significantly" versus its peers in the event of a repatriation tax holiday.


Finally, Pfizer's management team is committed to leveraging its global infrastructure and strong cash flow to "enhance financial prospects" through M&A deals, the analyst also stated. However, there is a risk that the company could overpay for potential M&A deals.

Related Links:

Analyst Prescribes Neutral Rating For Pfizer Shares

What Pharmaceuticals Spend On Lobbying To Influence Trump

Latest Ratings for PFE

May 2021SVB LeerinkMaintainsMarket Perform
Mar 2021SVB LeerinkMaintainsMarket Perform
Feb 2021DZ BankUpgradesHoldBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Posted-In: breast cancer David Risinger Drugmakers ibranceAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

CLVSHC Wainwright & Co.Maintains12.0
PDDDaiwa CapitalInitiates Coverage On180.0
RYAMRBC CapitalDowngrades11.0
XOMDZ BankUpgrades67.0
BWFGKeefe, Bruyette & WoodsUpgrades35.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at